Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking ...

'Mad Money' host Jim Cramer weighs in on stock including: Viper Energy, Nextracker, Trump Media, Eli Lilly, and Dutch Bros.

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.